Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study

Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study

Abstract Background Systemic and locoregional combination therapy has demonstrated promising outcomes for unresectable hepatocellular carcinoma (HCC); However, the best combination option remains unknown. This study compared the efficacy and safety of lenvatinib and tislelizumab versus atezolizumab...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongjie Cai, Song Chen, Shuangyan Tang, Yi Xiao, Feng Shi, Zhiqiang Wu, Ping Ma, Huanwei Chen, Wenquan Zhuang, Wenbo Guo
Format: Article
Language:English
Published: Springer 2025-02-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Combination therapy
Hepatic artery infusion chemotherapy
Hepatocellular carcinoma
Systemic therapy
Transarterial embolization
Online Access:https://doi.org/10.1007/s00262-025-03942-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-03942-3

Similar Items